Abstract: Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose. Also disclosed is an injectable aqueous pharmaceutical formulation comprising a therapeutically effective amount of trehalose.

Abstract: The invention provides a lipid bilayer mimicking the lipid composition of the placenta. The lipid composition provides an in vitro placenta model using the lipid composition of the placental cell membrane.

Abstract: The invention provides a method of karyotyping (for example for the detection of trisomy) a target cell to detect chromosomal imbalance therein, the method comprising: (a) interrogating closely adjacent biallelic SNPs across the chromosome of the target cell (b) comparing the result at (a) with the SNP haplotype of paternal and maternal chromosomes to assemble a notional haplotype of target cell chromosomes of paternal origin and of maternal origin (c) assessing the notional SNP haplotype of target cell chromosomes of paternal origin and of maternal origin to detect aneuploidy of the chromosome in the target cell. Also provided are related computer-implemented embodiments and systems.

Abstract: Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or esters. Advantageously, methods provided herein mitigate the antigenicity of the bioprosthetic tissue while leaving the overall tissue structure substantially undisturbed, and thereby enhance the durability, safety and performance of the bioprosthetic implant.

Abstract: An automated bioreactor system for decellularizing an organ includes a main chamber for containing the organ. The system further includes a reagent chamber containing a liquid phase reagent. A reagent conduit delivers the liquid phase reagent to the main chamber, and a perfusion conduit delivers the reagent from the reagent outlet in the main chamber into the organ. A perfusion pump drives the flow of the reagent. A perfusion pressure sensor detects a pressure of the flowing reagent. A control system controls the perfusion pump to drive the flow of the reagent based on a received input representative of a desired pressure and a received input of the detected pressure. The control system may automatically perform all of the steps of a decellularization protocol based on sensor input. An automated waste decontamination system may also be provided.

Abstract: The present invention solves the following problems [1] to [3] found in conventional methods of preparing a three dimensional structure (organ primordium) by coculturing functional cells with umbilical cord-derived vascular endothelial cells and bone marrow-derived mesenchymal cells: [1] the quality of resultant organ primordia varies greatly depending on donors; [2] the growth capacities of cell sources are limited; and [3] it is difficult to secure immunocompatibility because cells are derived from different sources. An organ bud prepared from vascular cells, mesenchymal cells and tissue or organ cells, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells. A method of preparing an organ bud, comprising culturing vascular cells, mesenchymal cells and tissue or organ cells in vitro, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells.

Abstract: The present disclosures provides methods for decreasing injuries associated with intraoperative hypotension by intravenously administering to a subject a therapeutically effective amount of a fat emulsion, following a period of intraoperative hypotension and after the subject's mean arterial blood pressure has recovered. The disclosure also provides methods for preventing injuries associated with intraoperative hypotension, particularly for surgical candidates that have an increased risk for intraoperative hypotension. Non-limiting examples of injuries contemplated herein include myocardial injury, myocardial infarction, and acute kidney injury.

Abstract: The invention provides a system for normothermic, ex vivo restoration and preservation of an intact mammalian brain, and other organs. In certain aspects, the system is capable of preserving a brain as well as other organs, maintaining cellular integrity and cellular function for hours post mortem or after global ischemia. The invention also provides synthetic brain perfusate formulations, including a novel brain perfusion medium (BPM), which are able to reduce reperfusion injury, stimulate recovery from hypoxia, prevent edema and metabolically support the energy needs of brain function.

Abstract: Apparatus for perfusion of multiple types of organs include base unit configured to removably couple with a perfusion module for perfusing an organ. The base unit has conduits for connecting a source of a perfusate to the organ to circulate the perfusate through the organ; first and second pumps coupled to the conduits for driving circulation of the perfusate in the conduits; and a controller configured and connected for controlling the first and second pumps to regulate the circulation of the perfusate through the organ. The controller is operable to control the first and second pumps to perfuse the organ in accordance with organ specific perfusion parameters. The organ specific perfusions parameters are selected based on the type of the organ, and may be selected by an operator for at least two organ types selected from the group of heart, liver, kidney and lung.

Abstract: A system and method are provided for wet storage of tissue. In an embodiment, a solution for the wet preservation of tissue may include between about 0.1% to about 50% by volume dimethyl sulfoxide (DMSO) and one or more soluble monovalent or divalent metal cationic salts. A wet-preserved tissue and method for preparing the wet-preserved tissue for ultimate use, is also provided.

Abstract: The invention relates to a blood treatment device for carrying out an extracorporeal blood treatment in which blood is guided in a blood guidance device having a main blood line and at least one secondary line, the latter being fluidically connected to the main blood line and the main blood line having a dialyzer and, downstream from the dialyzer, a blood treatment element, wherein the blood treatment device has a control device; and a pump configuration, which is equipped for generating blood flows in the main blood line and also in the at least one secondary line, wherein the control device is designed to operate the pump configuration in such a way that a first blood flow rate in the dialyzer is decoupled from a second blood flow rate in the blood treatment element. Furthermore, the invention relates to a blood guidance device for cooperation with the blood treatment device as well as for a blood treatment system.

Abstract: This invention relates to the preservation of vascularized tissues and organs by freezing or by vitrification; to organ and tissue cryopreservation or banking; and to tissue and organ perfusion with cryoprotective agents (also known as cryoprotectants).

Abstract: A method for organ and tissue chimerization using bone marrow cellular treatment, which avoids rejection of transplanted organs and diminishes or suspends the use of immunosuppressant drugs in patients subjected to transplant procedures. The method comprises washing the organ in an electrolyte solution. A further step of washing the organ in a wash solution. The organ is then placed in a culture solution and incubated with bone marrow cells.

Abstract: Aspects of the disclosure relate to rotating bioreactors and articles and methods that are useful for adapting a rotating bioreactor for use with tissues or scaffolds of different sizes. In some embodiments, bioreactors comprising a reservoir and an arbor assembly are provided herein, in which the arbor assembly comprises a rotatable support to which a tissue or tissue scaffold can be attached.

Abstract: Provided herein are compositions and methods to make and use engineered cells, for the purpose of increasing the cell density of a culture comprising metazoan cells and for the production of a cultured edible product.

Abstract: Presented is an airway organ bioreactor apparatus, and methods of use thereof, as well as bioartificial airway organs produced using the methods, and methods of treating subjects using the bioartificial airway organs. The bioreactor comprises: an organ chamber; an ingres line connecting the organ chamber and a reservoir system and comprising an arterial line, a venous line and a tracheal line; an egress line connecting the chamber and the reservoir system, pumps in ingress and egress lines; a controller to control fluid exchange; a chamber pressure sensor connected to the organ chamber.

Abstract: A bio-information estimating apparatus includes a sensor part configured to measure a pulse wave signal from an object, a contact force that is applied by the object to the sensor part, and a contact area of the object that is applied to the sensor part, and a processor configured to obtain a first feature value, based on a first change in the contact area with respect to a second change in the contact force, obtain a second feature value, based on the pulse wave signal, and estimate bio-information, based on the first feature value and the second feature value.

Abstract: The present invention provides a decellularized collagenous tissue and a method for processing an artificial heart valve containing the decellularized collagenous tissue. The method comprises immersing the decellularized collagenous tissue in a preservation liquid containing an ionic liquid until the size of the decellularized collagenous tissue remains stable in a non-liquid environment. The present invention also provides a preservation method, comprising immersing the decellularized collagenous tissue or the artificial heart valve containing decellularized collagenous tissue in the preservation liquid containing ionic liquid until the size of the collagen tissue remains stable in the non-liquid environment. The present invention also provides a decellularized collagenous tissue and an artificial heart valve containing the decellularized collagenous tissue processed by the method described above.

Abstract: A tissue graft container is provided having an interior space and including a vent which allows fluid (liquid and vapor) to escape from the container during drying of the tissue graft. The vent may be one or more apertures, one or more elongated openings, or a combination thereof, through one or more components of the container. A tissue graft packaging system having a retainer including first and second members with respective first and second pluralities of channels, and configured to removeably interconnect the first and second members in a closed configuration. The first and second pluralities of channels create a continuous interior space. The retainer further includes a vent, such as apertures, slits, etc., through one or both of the first and second retainers, for allowing moisture to escape from the retainer during the drying of a tissue graft contained within the continuous interior space of the retainer.

Abstract: Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets.

Abstract: Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.

Abstract: This invention relates to an aqueous solution for preserving and rinsing organs to be transplanted comprising: sodium (Na+) ions at a concentration between 30 and 150 mmol·L?1; potassium ions (K+) at a concentration between 10 and 40 mmol·L?1; polyethylene glycol with a molecular weight of 35,000 g·mol-1 (PEG 35000) at a concentration between 2 and 5 g·L?1.

Abstract: The invention relates to a method for polar body injection, which comprises removing a polar body from a first egg cell and injecting the polar body into a second egg cell that is in a fertilizable state.

Abstract: There is described a preservation solution for the preservation of cells, tissues and/or organs, said solution comprising: (i) water for injection; (ii) at least one saccharide; (iii) at least one component with pH buffer properties; (iv) optionally at least one component with calcium transport blocking properties or an anti-calcium action activity; (v) salicylic acid, in free form or in salt form, or aspirin; and (vi) glutamic acid, in free form or in salt form, or glutamine; provided that acetamide is absent and/or if aspirin is present glutamine is absent and if glutamine is present aspirin is absent.

Abstract: The present disclosures provides methods for decreasing injuries associated with intraoperative hypotension by intravenously administering to a subject a therapeutically effective amount of a fat emulsion, following a period of intraoperative hypotension and after the subject's mean arterial blood pressure has recovered. The disclosure also provides methods for preventing injuries associated with intraoperative hypotension, particularly for surgical candidates that have an increased risk for intraoperative hypotension. Non-limiting examples of injuries contemplated herein include myocardial injury, myocardial infarction, and acute kidney injury.

Abstract: A protocol for the cryopreservation of high viscosity biological samples, preferably of spermatic samples of crustaceans or insects, that enables maintaining intact the physical properties of the original sample preserving the viability of the sperm packet.

Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Abstract: The embodiments described herein include methods and formulations for treating lung and brain injury. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from placental tissue. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function.

Abstract: Systems and methods for assembling a plurality of tissue grafts are provided. A method includes harvesting the plurality of micro tissue grafts from a donor site, arranging the plurality of micro tissue grafts in a desired orientation, forming a tissue construct containing the plurality of micro tissue grafts arranged in the desired orientation, and applying the tissue construct to a recipient site.

Abstract: Disclosed herein are compositions, devices, and methods that provide cellular materials in ready to use formats for experimental, therapeutic, and tissue engineering protocols. For example, compositions containing frozen or non-frozen cell present as aggregates are disclosed. Also disclosed a compositions containing cellular materials that after storage are suitable for dispersion, e.g. by 3D printing. Also disclosed is a kit for producing bioink compositions. Also disclosed is a closed system device comprising a cell material composition described herein.

Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.

Abstract: The invention comprises several embodiments of a multi-step method for extracting mineral and protein components from a mineralized biocomposite material, including at least the steps of: extracting proteins and minerals from a material into a first solution by contacting or immersing it with the first solution, comprising one or more of a demineralization solution and a salt solution; obtaining a first solid portion from the first solution, by separating the solid and liquid portions; extracting proteins and minerals from the first solid portion into a second solution by contacting or immersing it with the second solution, comprising one or more of a demineralization solution and a salt solution; and obtaining a second solid portion from the second solution by separating the liquid and solid portions. Each of these embodiments may be operated in succession to any of the other embodiments to create custom optimized extraction processes.

Abstract: A bone bioactive composition and kits comprising the composition, means for applying it and/or a metal implant are provided. The bone bioactive composition comprises a water-based salt solution comprising sodium dihydrogen phosphate and sodium chloride, and may also comprise additional elements. The composition and the kits are useful for promoting osteogenesis, particularly when a metal implant is used but also in case of periodontal diseases.

Abstract: A method of ameliorating, inhibiting, preventing, or reducing male infertility in a subject undergoing or in need of chemotherapy by administering to the subject a granulocyte colony-stimulating factor in a protective amount, prior to, during or after administration of one or more chemotherapeutic agents to the subject.

Abstract: Provided in some aspects are methods and compositions for preserving platelets or other cells. In some embodiments, a platelet storage media or cell storage media may comprise a low molecular weight polyethylene glycol (e.g. PEG-400) to allow for extended storage and/or refrigeration of the platelets or cells.

Abstract: Provided herein are methods of producing an acellular tissue product wherein the method can include the step of inducing apoptosis and washing the tissue after induction of apoptosis with a tonic solution. Also provided herein are acellular tissue products produced by the methods provided herein and methods of administering the acellular tissue products to a subject in need thereof.

Abstract: An aqueous organ preservation solution includes taurine and L-alanine-L-glutamine and glutamic acid. The organ preservation composition can be stored in a solid state, for example in the form of small particles (e.g. a powder or micronized powder), and be dissolved in water, thereby instantly providing a ready-to-use organ preservation solution.

Abstract: Broadly speaking, embodiments of the present technique provide apparatus for controlling ice formation, such as during the processes of cryopreservation and freeze drying. In particular, the apparatus provides a mechanism to deliver an ice nucleating material into a biological sample that is to be preserved, without allowing the ice nucleating agent to contact or contaminate the biological matter within the sample.

Abstract: The present invention relates in a first aspect to a method for the purification of biological macromolecular complexes. Typically, no chromatography steps are applied. That is, the present invention relates to a method for the purification of biological macromolecular complexes Furthermore, the present invention relates to a method for crystallization of biological macromolecular complexes comprising the step of purification as described followed by crystallization in a reservoir solution containing a water-soluble polymer. Furthermore, purified biological macromolecular complexes obtainable by the method according to the present invention are provided as well as crystallized biological macromolecular complexes. Finally, a method for determining the suitability of a candidate compound for inhibiting the 20S proteasome of an individual is provided.

Abstract: An automated life science laboratory or a storage facility for biological specimens may be located together with or in close proximity to a data center. The location of the data center, the automated life science laboratory, and the storage facility may be a location in which land and/or electricity are less expensive than locations where the biological specimens are collected. The automated life science laboratory may have a high-capacity data connection to the data center. The life science laboratory, storage facility, and the data center may share a connection to the electrical grid, an HVAC system, and/or a security perimeter. A biological specimen may be removed from storage at the storage facility, process by one or more biotechnology protocols at the automated life science laboratory, and data from the processing may be stored in the data center.

Abstract: Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets.

Abstract: The presently disclosed subject provides a biomimetic eye model, and methods of its production and use. In one exemplary embodiment, the biomimetic eye model can include a scaffold having a convex curvature, a fluidic device coupled to the scaffold, a fabricated eyelid coupled to the fluidic device and a motor coupled to the fabricated eyelid. In certain embodiments, the scaffold can be impregnated with one or more keratocytes and a surface of the convex curvature of the scaffold can be covered with one or more layers of epithelial cells.

Abstract: A bone graft composition comprising a viable, osteogenic cellular material combined with a viscous cryoprotectant that includes a penetrating cryoprotective agent and a non-penetrating cryoprotective agent. The viscosity of the cryoprotectant is such that the composition is malleable, cohesive and capable of being formed into desired shapes.

Abstract: Compositions for maintaining cellular integrity especially in cases of cryopreservation and multiple freeze/thawing cycles are provided. In addition, the compositions can be used in various media for a variety of applications.

Abstract: Disclosed herein are muscle implants and methods of making muscle implants comprising one or more decellularized muscle matrices. The muscle matrices can, optionally, be joined to one or more decellularized dermal matrices. The muscle implants can be used to enhance muscle volume or to treat muscle damage, defects, and/or disorders. The decellularized muscle matrices in the implants retain at least some of the myofibers found in a muscle tissue prior to processing.

Abstract: Provided is a tissue slicing device having a first motor, a filling assembly, a filter, a pipe, and a cutter. The filling assembly includes a tube and a piston rod movably inserted through the tube. One end of the piston rod abuts against the first motor. The filter is located at an end of the tube opposite the first motor. The pipe is located at a common side of the first motor and the filling assembly, and includes a nozzle located at an end of the pipe and proximal to an end of the filter opposite the filling assembly. The cutter is proximal to the filter. The guiding body is located at the end of the tube opposite the first motor. Provided is an apparatus having the tissue slicing device, such that manpower and time can be saved, and the tissue slicing degree can be unified.

Abstract: The invention provides, in various embodiments, systems, devices and methods relating to ex-vivo organ care. In certain embodiments, the invention relates to maintaining an organ ex-vivo at near-physiologic conditions. The present application describes a method for using lactate measurement in the arterial and the venous blood lines of the Organ Care System Heart perfusion device to evaluate the: 1) The overall perfusion status of an isolated heart and 2) The metabolic status of an isolated heart and 3) the overall vascular patency of an isolated donor heart. This aspect of the present invention uses the property of myocardial cell's unique ability to produce/generate lactate when they are starved for oxygen and metabolize/utilize lactate for energy production when they are well perfused with oxygen.

Abstract: The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.

Abstract: The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.